| Andersen, Henning R |
| Recruiting | 4 | 60 | Europe | Immunoglobulin | University of Aarhus, Rigshospitalet, Denmark, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital | CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | 12/30 | 12/30 | | |
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 110 | Europe, Canada, US, RoW | Efgartigimod IV, Placebo IV | argenx | Generalized Myasthenia Gravis | 07/25 | 07/27 | | |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Terminated | 3 | 260 | Europe, Canada, US | Losmapimod, Placebo oral tablet | Fulcrum Therapeutics | Facioscapulohumeral Muscular Dystrophy (FSHD) | 11/24 | 11/24 | | |
| Recruiting | 2 | 80 | Europe, US | NMD670, Placebo | NMD Pharma A/S | Charcot-Marie-Tooth Disease | 03/26 | 03/26 | | |
| Recruiting | N/A | 108 | Europe | 6-months of medically assisted glycemic improvement, Bariatric surgery | University of Aarhus | Diabetes Mellitus, Obesity, Chronic Hyperglycaemia, Weight Loss, Diabetic Myopathy, Sarcopenia | 09/25 | 12/25 | | |
| Yu, Xueqing |
AURORA, NCT03214731: Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis |
|
|
| Recruiting | 4 | 90 | RoW | Artesunate, Art, placebo | Sun Yat-sen University, The First People's Hospital of Yunnan, The First Affiliated Hospital of Nanchang University, General Hospital of Ningxia Medical University, First Affiliated Hospital of Fujian Medical University, Shenzhen Second People's Hospital, The Third Xiangya Hospital of Central South University, Tongji Hospital | Lupus Nephritis | 09/22 | 09/22 | | |
LUMINA, NCT03200210: Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients |
|
|
| Recruiting | 4 | 548 | RoW | Febuxostat, Febuxostat Tablets, Placebo | Sun Yat-sen University | Hyperuricemia | 12/22 | 12/22 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
NCT06016036: SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease |
|
|
| Completed | 3 | 156 | RoW | SAL-0951, SAL-0951 group, Placebo, Placebo phase | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Renal Anemia in Non-dialysis Chronic Kidney Disease | 10/21 | 02/22 | | |
| Recruiting | 3 | 486 | RoW | SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo | Shanghai Hengrui Pharmaceutical Co., Ltd. | Secondary Hyperparathyroidism | 06/25 | 07/25 | | |
NCT05663411: A Study of SHR6508 in Secondary Hyperparathyroidism |
|
|
| Active, not recruiting | 2 | 75 | RoW | SHR6508, Cinacalcet | Shanghai Hengrui Pharmaceutical Co., Ltd. | Secondary Hyperparathyroidism | 10/23 | 11/23 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT06676631: NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis |
|
|
| Not yet recruiting | 1 | 18 | NA | NK 010 or NK042, NK010 or NK042 infusion, Rituximab, RTX | Guangdong Provincial People's Hospital | Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis | 12/26 | 12/27 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Recruiting | N/A | 903 | RoW | Dialysis modality | Sun Yat-sen University | End Stage Renal Disease on Dialysis, Peritoneal Dialysis, Hemodialysis | 12/21 | 12/21 | | |
NCT05190848: Correlation of Microbiome and Metabonomics With IgA Nephropathy |
|
|
| Recruiting | N/A | 600 | RoW | | Guangdong Provincial People's Hospital | IgA Nephropathy | 12/24 | 12/24 | | |
| Recruiting | N/A | 10000 | RoW | No intervention | Sun Yat-sen University | IgA Nephropathy | 12/26 | 12/26 | | |
NCT03001973: High Quality Evidence of Chinese Lupus Nephritis (HELP) |
|
|
| Recruiting | N/A | 5000 | RoW | No Intervention | Sun Yat-sen University | Lupus Nephritis | 12/26 | 12/26 | | |
NCT02989298: Peritoneal Dialysis Registration System (PERSIST) |
|
|
| Recruiting | N/A | 10000 | RoW | No intervention | Sun Yat-sen University | ESRD, Disorders Associated With Peritoneal Dialysis | 12/26 | 12/26 | | |
| Recruiting | N/A | 30000 | RoW | No intervention | Sun Yat-sen University | Haemolyses and Related Conditions | 12/26 | 12/27 | | |
| Recruiting | N/A | 5000 | RoW | No intervention | Sun Yat-sen University | Nephrotic Syndrome | 12/26 | 12/28 | | |
NCT05188885: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases |
|
|
| Recruiting | N/A | 90000 | RoW | | Guangdong Provincial People's Hospital | Chronic Kidney Disease | 12/26 | 12/28 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Wu, Wei |
| Not yet recruiting | 4 | 336 | RoW | Danning Tablet, Biliflow (NPN 80073325, manufactured by Shanghai Hutchison Pharmaceuticals Limited) | Eastern Hepatobiliary Surgery Hospital | Polyps Gallbladder | 08/24 | 11/24 | | |
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects |
|
|
| Recruiting | 3 | 312 | RoW | Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999） | Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang | Advanced HBV-Related Hepatocellular Carcinoma (HCC) | 12/22 | 12/22 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Shuxuening Injection, Placebo | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 06/25 | 12/26 | | |
NCT06277050: Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 264 | RoW | Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy | 02/29 | 02/30 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
NCT04557020: Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC |
|
|
| Recruiting | 3 | 200 | RoW | PD-1 antibody, Gemcitabine, Cisplatin, IMRT | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 03/26 | 03/26 | | |
| Recruiting | 2 | 200 | RoW | BEBT-109 Capsule, KCBT-1083 | BeBetter Med Inc | Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | 12/25 | 06/26 | | |
NCT04741165: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 72 | RoW | HX008, Bevacizumab, AVASTIN®, Lenvatinib, LENVIMA® | Taizhou Hanzhong biomedical co. LTD | Hepatocellular Carcinoma | 04/22 | 10/22 | | |
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 238 | RoW | MRG003, Capecitabine tablets, Docetaxel injection | Shanghai Miracogen Inc. | Recurrent or Metastatic Nasopharyngeal Carcinoma | 10/24 | 02/25 | | |
NPC-CR01, NCT05128201: Consolidative Radiotherapy Combined With Camrelizumab and Chemotherapy for Oligometastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 63 | RoW | consolidative radiotherapy, local consolidative radiotherapy | Jiangxi Provincial Cancer Hospital | Oligometastatic Disease | 05/25 | 05/26 | | |
NCT05339321: Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC |
|
|
| Recruiting | 1 | 36 | RoW | SCG101, PD1/PD-L1 checkpoint inhibitor | Peking Union Medical College Hospital | Hepatocellular Carcinoma | 07/23 | 12/23 | | |
| Recruiting | 1 | 160 | US | Abstinence from alcohol, Usual drinking, Intravenous Alcohol, 6.0& (v/V) ethanol solution | Indiana University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 08/25 | 08/25 | | |
TQB2618-AK105-Ib-04, NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
NCT06375538: Ultrasound Evaluations of Diaphragm and Intercostal Muscle to Predict the Failure of High-Flow Nasal Cannula Therapy |
|
|
| Recruiting | N/A | 200 | RoW | | Shanghai Zhongshan Hospital | High-flow Nasal Cannula, Ultrasound Evaluation, Diaphragm and Intercostal Muscle | 08/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
NCT04353063: Muscle Wasting in Children and Adolescents With Cancer |
|
|
| Recruiting | N/A | 440 | RoW | Multidisciplinary care with a personalized care | National Taiwan University Hospital | Cachexia; Cancer, Muscle Wasting, Child Development, Adolescent Development | 07/23 | 07/23 | | |
NCT04724148: Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension |
|
|
| Recruiting | N/A | 4 | RoW | Fentanyl | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Lishui hospital of Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Zhejiang University | Liver Cirrhosis, Portal Hypertension, Pain | 11/24 | 11/24 | | |
NCT05316311: A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Recruiting | N/A | 194 | RoW | CERENOVUS ENTERPRISE 2 Intracranial Stent | Medos International SARL | Intracranial Atherosclerosis | 02/26 | 04/26 | | |
| Li, Yanfang |
NCT04883177: Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101) |
|
|
| Completed | N/A | 1000 | RoW | | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Huashan Hospital, The Sixth People's Hospital of Shenyang City, Xingtai City People's Hospital, Jinchang Central Hospital, Baoding People's Hospital, The Third People's Hospital of Zhenjiang City, Shanxi Bethune Hospital, Wuhan Jinyintan Hospital, Jincheng People's Hospital, The Third People's Hospital of Tibet Autonomous Region, People's Hospital of Ningxia Hui Autonomous Region, Fuling Central Hospital of Chongqing City, Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region, The Central Hospital of Lishui City, The Third People's Hospital of Linfen City, Yibin First People's Hospital, Jingzhou Central Hospital, Wuxi Fifth People's Hospital, Qingyang People's Hospital, The First Affiliated Hospital of Anhui Medical University, Beilun Hospital of Traditional Chinese Medicine, Henan Provincial People's Hospital, Qingdao Sixth People's Hospital, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Beijing YouAn Hospital, The First People's Hospital of Taicang, The Third People's Hospital of Taiyuan, Tianjin Second People's Hospital, Tianjin Third Central Hospital, Qishan Hospital of Yantai City, Affiliated Hospital of Yunnan University, The First People's Hospital of Yunnan, The Fourth Affiliated Hospital of Zhejiang University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Chongqing Medical University | COVID-19, Liver Disease, Vaccine Reaction | 01/22 | 05/22 | | |
| Liu, Fengbin |
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule |
|
|
| Recruiting | 4 | 480 | RoW | Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Functional Dyspepsia, Postprandial Distress Syndrome | 12/23 | 12/23 | | |
| Lin, LIzhu |
NCT05229809: Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer |
|
|
| Recruiting | 4 | 212 | RoW | Yiqi Wenyang Jiedu prescription, Simulation agent of Yiqi Wenyang Jiedu prescription | Jie Li | Gastric Carcinoma | 07/23 | 07/24 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT05765825: Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC |
|
|
| Recruiting | 2 | 61 | RoW | serplulimab, HLX10, Cisplatin, Cisplatin injection, Carboplatin, Carboplatin injection, Etoposide, Etoposide injection, Thoracic radiation therapy (TRT), low-dose radiotherapy | Sichuan University | Extensive-stage Small-cell Lung Cancer | 06/24 | 12/25 | | |
| Yang |
| Recruiting | 3 | 472 | RoW | Atropine Sulfate 01, LPTAT01, Atropine Sulfate 02, LPTAT02, Atropine Sulfate 03, LPTAT03, Placebo, LPTAT04 | LitePharmTech Co., Ltd. | Myopia, Children | 06/23 | 12/23 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT06174402: Fenofibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis |
|
|
| Recruiting | 2/3 | 184 | RoW | Fenofibrate, Placebo, UDCA | Han Ying | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
WU-KONG1, NCT03974022: Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation |
|
|
| Active, not recruiting | 1/2 | 315 | Europe, Canada, Japan, US, RoW | Sunvozertinib, DZD9008 | Dizal Pharmaceuticals | Non-Small Cell Lung Cancer | 07/24 | 07/25 | | |
OCU400-101, NCT05203939: Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis |
|
|
| Active, not recruiting | 1/2 | 22 | US | OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose | Ocugen | Retinitis Pigmentosa, Leber Congenital Amaurosis | 12/24 | 12/24 | | |
NCT05954624: Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid |
|
|
| Completed | 1 | 49 | RoW | Digoxin, Rosuvastatin, ZSP1273, Itraconazole, Probenecid | Guangdong Raynovent Biotech Co., Ltd | Drug Drug Interaction | 11/23 | 11/23 | | |
NCT06745973: An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B |
|
|
| Not yet recruiting | 1 | 20 | RoW | EPI-003 | Epigenic Therapeutics, Inc | Chronic Hepatitis B | 12/26 | 12/26 | | |
| Not yet recruiting | 1 | 24 | RoW | [225Ac]Ac-DOTATATE | Peking University Cancer Hospital & Institute, Sinotau Pharmaceutical Group | Neuroendocrine Tumors | 07/25 | 03/26 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
NCT05714566: Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients |
|
|
| Recruiting | N/A | 100 | RoW | Clostridioides difficile toxin detection | RenJi Hospital | Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia | 06/24 | 12/24 | | |
| Lin, Changsong |
| Recruiting | N/A | 50000 | RoW | No additional intervention will be administered. | Peking Union Medical College Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Tianjin First Central Hospital, Hebei Medical University Third Hospital, Dalian Hospital of Chinese Traditional and Western Medicine, The Second Affiliated Hospital of Harbin Medical University, Peking University Third Hospital, Beijing Shijingshan Hospital, The Second Medical Center of The General Hospital of the People's Liberation Army, Huamei hospital, University of Chinese Academy of Sciences, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, Ruijin Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Nantong University, Nantong First People's Hospital, Shanghai Changzheng Hospital, Wuhan Union Hospital, China, Central South University, Guangdong Provincial People's Hospital, Nanfang Hospital of Southern Medical University, Lunjiao Hospital of Shunde Foshan, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou Second Hospital, Second Affiliated Hospital of Guangzhou Medical University, Shenzhen Second People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Sichuan Provincial People's Hospital, West China Fourth Hospital, Sichuan Province Orthopedic Hospital, The Second Affiliated Hospital of Chongqing Medical University, Daping Hospital, Army Medical Center of PLA, Guizhou Provincial Orthopedics Hospital, First Affiliated Hospital Xi'an Jiaotong University, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, The First Affiliated Hospital of Zhengzhou University | Osteoporosis, Osteoporotic Fractures | 12/24 | 12/24 | | |
| Chen, Hanrui |
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 4 | 334 | RoW | Kanglaite Injection+Chemotherapy, Chemotherapy | Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences | NSCLC | 03/22 | 05/22 | | |
NCT05897749: Clinical Study on the Effect of Brucea Javanica Oil Emulsion Injection on the Survival of Patients With Advanced Colorectal Cancer Who Failed to Receive Multi-line Treatment |
|
|
| Recruiting | 4 | 60 | RoW | Brucea javanica oil emulsion injection, The best supportive treatment | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Colorectal Cancer, Chinese Herbal Medicine, Progression-free Survival, Quality of Life | 12/25 | 12/25 | | |
NCT06461338: Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study |
|
|
| Not yet recruiting | N/A | 60 | RoW | acupuncture, Sham acupuncture | Guangzhou University of Traditional Chinese Medicine, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Jiangsu Province Hospital of Traditional Chinese Medicine | Non-small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma | 02/25 | 09/26 | | |
| Yang, Zhongqi |
NCT04983043: Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure |
|
|
| Completed | 2 | 228 | RoW | Low dose QiShen YiQi Dripping Pills 3 bags, Low dose group, High dose QiShen YiQi Dripping Pills 3 bags, High dose group, QiShen YiQi Dripping Pills placebo 3 bags, Placebo group | Tasly Pharmaceutical Group Co., Ltd | Chronic Heart Failure With Reduced Ejection Fraction | 11/24 | 11/24 | | |
| Chang, Ting |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Recruiting | 2/3 | 104 | RoW | B007, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Generalized Myasthenia Gravis | 06/26 | 06/26 | | |
tMG-E, NCT05716035: Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis |
|
|
| Recruiting | 2/3 | 64 | RoW | Tocilizumab Injection | Tang-Du Hospital | Myasthenia Gravis, Generalized | 07/24 | 12/24 | | |
tMG, NCT05067348: Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis |
|
|
| Recruiting | 2 | 64 | RoW | Tocilizumab Injectable Product | Tang-Du Hospital | Myasthenia Gravis, Generalized | 03/24 | 09/24 | | |
NCT05343481: Efficacy of VTP-300 in Chronic Hepatitis B Infection |
|
|
| Active, not recruiting | 2 | 120 | RoW | ChAdOx1-HBV, MVA-HBV, Nivolumab, Opdivo 10mg/ml concentrate for solution for infusion | Barinthus Biotherapeutics | Chronic Hepatitis B | 02/25 | 10/26 | | |
NCT06371040: Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis |
|
|
| Recruiting | 1 | 12 | RoW | CD19-BCMA Targeted CAR-T Dose 1, CD19-BCMA Targeted CAR-T Dose 2 | Ting Chang, MD | Myasthenia Gravis | 03/25 | 12/26 | | |
NCT05581485: Evaluation the Efficiency of Intravenous Dexmedetomidine Under HFNO Without Intubation in Laryngoscope Microsurgery |
|
|
| Recruiting | N/A | 60 | RoW | Non-intubated Laryngomicrosurgery | Kaohsiung Veterans General Hospital. | Dexmedetomidine | 12/24 | 12/24 | | |
| Recruiting | N/A | 1500 | RoW | | Huashan Hospital, China Alliance for Rare Diseases, National Center for Neurological Disorders (China), China myasthenia gravis collaborating group (CMGCG) | Myasthenia Gravis | 02/34 | 01/35 | | |
| Obal, Izabella |
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis |
|
|
| Recruiting | 3 | 235 | Europe, Canada, Japan, US, RoW | Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918 | Regeneron Pharmaceuticals | Generalized Myasthenia Gravis | 05/25 | 03/28 | | |
| Li, Suihui |
NCT06315101: Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China |
|
|
| Completed | N/A | 142 | RoW | Chinese Herbal Medicine | Guangzhou University of Chinese Medicine | Unresectable Hepatocellular Carcinoma | 12/23 | 12/23 | | |
